Participation of renal and circulating endothelin in salt-sensitive essential hypertension-Reference-Cited by-同舟云学术

Participation of renal and circulating endothelin in salt-sensitive essential hypertension

Published:2002-06-25 Issue:7 Volume:16 Page:459-467
ISSN:0950-9240
Container-title:Journal of Human Hypertension
language:en
Short-container-title:J Hum Hypertens

Author:

Elijovich F,Laffer C L

Publisher

Springer Science and Business Media LLC

Subject

Internal Medicine

Link

http://www.nature.com/articles/1001419.pdf

Reference103 articles.

1. Weinberger MH, Fineberg NS . Sodium and volume sensitivity of blood pressure: age and pressure change over time Hypertension 1991; 18: 67–71

2. Weinberger MH, Stegner JE, Fineberg NS . A comparison of two tests for the assessment of blood pressure responses to sodium Am J Hypertens 1993; 6: 179–184

3. Grim CE et al. An approach to the evaluation of genetic influences on factors that regulate arterial blood pressure in man Hypertension 1980; 2: I34–I42

4. Weinberger MH et al. Definitions and characteristics of sodium sensitivity and blood pressure resistance Hypertension 1986; 8: II127–II134

5. Kawasaki T et al. The effect of high-sodium and low-sodium intakes on blood pressure and other related variables in human subjects with idiopathic hypertension Am J Med 1978; 64: 193–198

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment;Clinical Drug Investigation;2019-08-21

2. Renal Hypertension;Encyclopedia of Endocrine Diseases;2019

3. Role of 20-Hydroxyeicosatetraenoic Acid in Mediating Hypertension in Response to Chronic Renal Medullary Endothelin Type B Receptor Blockade;PLoS ONE;2011-10-07

4. Synthesis and in vitro evaluation of ambrisentan analogues as potential endothelin receptor antagonists;Bioorganic & Medicinal Chemistry Letters;2011-07

5. TRC120038, a Novel Dual AT1/ETAReceptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats;International Journal of Hypertension;2011